News
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more effective drug, better execution, some keener pricing and a stronger pipeline.
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
3don MSN
Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for ...
The immediate market reaction to Novo Nordisk's earnings report was a positive one. As of 7 a.m. EDT, a few hours after the earnings release, shares of the drugmaker were up by about 5%. In short, the ...
Korro Bio is laying off a fifth of its workforce as the Novo Nordisk-partnered biotech funnels resources to its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback